News and Announcements
Tax Breaks for Investment in The Pulse IQ Pty Ltd
- Published November 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- ESIC ruling gives future investors generous tax benefits
Experience the Pulse has been granted Early Stage Innovation Company (ESIC) status by the Australian Taxation Office entitling its future investors to generous tax benefits.
On 1 July 2016, The Australian Government introduced favourable tax concessions for investors who support ESIC. The changes aim to encourage a culture of entrepreneurship and growth in Australia.
To qualify as an ESIC, The Pulse had to prove to the government that it had high growth potential, was able to scale, addressed a broader than local market, and had significant competitive advantages.
Investors in an ESIC are eligible for a 20 percent tax offset (capped at $200,000 per investor per year for ‘sophisticated’ investors and $50,000 for other investors) and won’t be subject to capital gains tax for 10 years on the sale of an ESIC investment held at least 12 months.
About The Pulse IQ Pty Ltd
The Pulse IQ is a world first, device-agnostic platform for the delivery of immersive and collaborative Virtual Reality content for training and education.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
